An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
Clinical trial NCT02573467 · COMPLETED
Trial details
- NCT number
- NCT02573467
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-11-02
- Primary completion
- 2016-08-17
- Enrollment
- 211
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.